Drug
Alpelisib
Alpelisib: highest development phase Phase 2, developed by Gilead Sciences, Novartis. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Gilead Sciences, Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| Alpelisib NCT06997588 | Phase 2 | PIK3CA-related Overgrowth Spectrum (PROS) |
| Alpelisib NCT05143229 | Phase 1 | Breast Cancer |
Latest
Follow Alpelisib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.